JPS6344842A - O/w/o-type emulsified oil and fat composition - Google Patents
O/w/o-type emulsified oil and fat compositionInfo
- Publication number
- JPS6344842A JPS6344842A JP61189454A JP18945486A JPS6344842A JP S6344842 A JPS6344842 A JP S6344842A JP 61189454 A JP61189454 A JP 61189454A JP 18945486 A JP18945486 A JP 18945486A JP S6344842 A JPS6344842 A JP S6344842A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- fat composition
- phospholipid
- present
- type emulsified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 27
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 9
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims abstract description 3
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 abstract description 5
- 239000011732 tocopherol Substances 0.000 abstract description 4
- 229930003799 tocopherol Natural products 0.000 abstract description 4
- 235000010384 tocopherol Nutrition 0.000 abstract description 3
- 229960001295 tocopherol Drugs 0.000 abstract description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 46
- 235000019198 oils Nutrition 0.000 description 46
- 239000012071 phase Substances 0.000 description 24
- 239000003925 fat Substances 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 17
- 239000000839 emulsion Substances 0.000 description 13
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- -1 a- Zuyary Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 108010076119 Caseins Proteins 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 241000147041 Guaiacum officinale Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QHOPXUFELLHKAS-UHFFFAOYSA-N Thespesin Natural products CC(C)c1c(O)c(O)c2C(O)Oc3c(c(C)cc1c23)-c1c2OC(O)c3c(O)c(O)c(C(C)C)c(cc1C)c23 QHOPXUFELLHKAS-UHFFFAOYSA-N 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229940091561 guaiac Drugs 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Edible Oils And Fats (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明はリン脂質を安定に配合した油中水中油型乳化油
脂組成物に関し、更に詳細には内相油にリン脂質を含有
せしめた、成人病を予防することのできる油中水中油型
乳化油脂組成物に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to an oil-in-water type emulsified fat composition stably containing phospholipids, and more specifically, the present invention relates to an oil-in-water type emulsified fat composition containing phospholipids in an internal phase oil. The present invention relates to an oil-in-water emulsified oil composition that can prevent adult diseases.
（従来の技術）
リン脂質は生体膜の重要な構成成分であるだけでなく、
その２位にリノールやリルン酔等の高度不飽和脂肪酸を
含有すること及び３位にコリ／等の塩基を含有すること
から、栄養的に必須脂肪酸及びビタミン様物質の供給源
としても重要な食餌（事）成分である。また最、近動脈
硬化あるいは高脂血症の予防・治療にその構成脂肪酸の
作用以外にホスファチジルコリン、ホス７アチジルエタ
ノールアミン等のリン脂質自体が有効であることが明ら
かとなっている。(Conventional technology) Phospholipids are not only important constituents of biological membranes, but also
It is an important dietary source of nutritionally essential fatty acids and vitamin-like substances because it contains highly unsaturated fatty acids such as linole and linol in the second position, and bases such as coli in the third position. (thing) It is an ingredient. Furthermore, it has recently become clear that phospholipids themselves, such as phosphatidylcholine and phos-7-acylethanolamine, are effective in preventing and treating arteriosclerosis or hyperlipidemia, in addition to the effects of their constituent fatty acids.
しかし、これらリン脂質は単独ではその構成脂肪酸が酸
化され易く、生じた過酸化物が勾い、味を悪くすると共
に、これが生体内に取り入れられ次場合、生体膜を破壊
したり、組織に沈着し、生体機能の衰退を起し、疾患の
原因となってい友。However, when these phospholipids are used alone, their constituent fatty acids are easily oxidized, and the resulting peroxides become cloudy and taste bad.If these phospholipids are taken into the body, they can destroy biological membranes or deposit in tissues. However, it causes a decline in biological functions and becomes a cause of disease.
従来、過酸化物の生成を抑制する目的で、リン脂質ソフ
トゼラチンカプセル中あるいは、窒素雰囲気上保存した
り、また、トコフェロール等の抗酸化剤と共存せしめる
ことがおこなわれているが不充分であった。Conventionally, in order to suppress the production of peroxides, storage in phospholipid soft gelatin capsules or in a nitrogen atmosphere, or coexistence with antioxidants such as tocopherols have been carried out, but these efforts have not been sufficient. Ta.
したがって、リン脂質の生理作用を充分発揮さ 。 Therefore, the physiological effects of phospholipids are fully demonstrated.
せ、成人病予防効果を期待するためにリン脂質を安定化
させた組成物の開発が要望されていた。Therefore, there has been a demand for the development of a composition with stabilized phospholipids in order to expect the effect of preventing adult diseases.
不発間者らは、上記問題点全解決すぺ〈種々研究金おこ
なった結果、リン脂質會、内相油？水相中に乳化させた
水中油型エマルジョ／（以下ｒｏ、／ｗエマルジョン」
という１．更に外相油Ｏｔ中に乳化分散させて得た油中
水中油型エマルジョベ以下１− ｏ、 ／Ｗ１０．工々
ルジョｙＪ とい’））中に配合すればリン脂質、特に
その構成脂肪酸が安定化されることを見出し本発明を完
成した。The duds have solved all of the above problems.As a result of various research funds, phospholipid association, internal phase oil? Oil-in-water emulsion emulsified in an aqueous phase (hereinafter referred to as ro, /w emulsion)
1. Further, an oil-in-water emulsion obtained by emulsifying and dispersing in external phase oil Ot is as follows: 1-o, /W10. The present invention was completed by discovering that phospholipids, especially their constituent fatty acids, can be stabilized by incorporating them into phospholipids.
すなわち、本発明はリン脂質？内相油中に含有したこと
を特徴とする０、 ／Ｗ１０．型乳化油脂組成物會提供
するものである。In other words, does the present invention involve phospholipids? 0, /W10., characterized in that it is contained in the internal phase oil. The present invention provides a type emulsified oil and fat composition.
不発ψ１の０１ ／ Ｗ ／ ０２ Ｋ乳化油脂組成物
（以下「油脂組成物」という）に使用するり／脂質とじ
ては、ホスファチジルコリ／、ホスファチジルエタノー
ルアミン、ホスファチジルイノシトール、ホスファチジ
ン酸、ホスファチジルグリセロール。The lipids used in the 01/W/02K emulsified oil composition (hereinafter referred to as "oil composition") of misfired ψ1 include phosphatidylcoli/, phosphatidylethanolamine, phosphatidylinositol, phosphatidic acid, and phosphatidylglycerol.
スクイ／ゴミエリンが挙げられる。Examples include Sukui/Gomierin.
本発明の油脂組成物は、内相油に上記リン脂質を含有せ
しめる以外は公知の方法により調製することができる。The oil and fat composition of the present invention can be prepared by a known method except that the internal phase oil contains the above-mentioned phospholipid.
例えば、内相油（Ｏｌ）成分と水相（Ｗ） 成分？混
合し、予゛ｉ乳化後、これ會３０°〜ｓｏ’℃、好まし
くは５０°〜７０℃でホモゲナイザーにかけｏ、 ７ｙ
ｊエマルジョンｔ−得る。次いで外相油（０１）成分を
４０’〜７０℃、好ましくは５０°〜６０℃に加熱し、
これに上記 、／Ｗエマルジョンを加え混合後、急冷練
合せをすることにより製造される。For example, the internal phase oil (Ol) component and the water phase (W) component? After mixing and pre-emulsifying, the mixture is homogenized at 30° to 70°C, preferably 50° to 70°C.
j emulsion t-obtain. Then, the external phase oil (01) component is heated to 40° to 70°C, preferably 50° to 60°C,
The above-mentioned /W emulsion is added to this, mixed, and then rapidly cooled and kneaded.
内相油にはリン脂質のほかに抗酸化性の物質を加え、リ
ン脂質の効果と安定性をさらに向上させることが可能で
ある。抗酸化剤としては、−膜内に食品の抗酸化剤とし
て用いられている１コフエロール類、ブチルヒドロキシ
アニソール、ジブチルヒドロキシトルエン、ニリンルビ
／酸、エリソルビ／酸ナトリウム等が使用される。また
その他に抗酸化能？有する香辛料、生薬の抽出物、粉末
。In addition to phospholipids, antioxidant substances can be added to the internal phase oil to further improve the effectiveness and stability of phospholipids. As the antioxidant, monocopherols, butylhydroxyanisole, dibutylhydroxytoluene, nilin ruby/acid, erythorubi/sodium acid, etc., which are used as antioxidants in foods, are used in the membrane. Also, does it have other antioxidant properties? spices, herbal extracts, and powders.
精油抽し１″ｌ残渣等が用いられる。抗酸化能を有する
香〒料、生薬として・・マビシ科、ゆそうぼ〈（Ｇｕａ
ｊａｃｕｍ ｏｆｆｉｃｉｎａｌｌｅ ）に含有するグ
アヤク脂、ヒマワリ種子、大豆油等に含まれる天然トコ
フェロール、五倍子、没食子に含まれるタンニンの加水
分解産物である没食子酸、胡麻油に含まれるセザモール
綿実油に含まれるゴシポール、ａ−ズヤリー、セージ、
タイム、オレガノ等がある。これらの抗酸化性物質のう
ち、特にトコフェロール、ローズマリー、セージ等の生
薬・香辛料由来のものがよい。The 1"l residue of essential oil extraction is used. As a fragrance and herbal medicine with antioxidant ability...
guaiac oil contained in Jacum officinalle), natural tocopherol contained in sunflower seeds, soybean oil, etc., gallic acid which is a hydrolysis product of tannin contained in gallic acid, sezamol contained in sesame oil, gossypol contained in cottonseed oil, a- Zuyary, Sage;
Thyme, oregano, etc. Among these antioxidant substances, those derived from herbal medicines and spices such as tocopherol, rosemary, and sage are particularly good.
また、本発明の油脂組成物において用いられる油）信と
しては１食用油脂が好ましく、その種類については、特
に制限されず、大豆油、ナタネ油。Furthermore, the oil used in the oil and fat composition of the present invention is preferably an edible oil or fat, and its type is not particularly limited, such as soybean oil and rapeseed oil.
パーム油、コーン油、ｘ実油、ヤシ油、パーム核油等の
植物油脂類、乳脂２牛脂、ラード、魚油、鯨油等の動物
油脂類のいずれも使用することができ、また、これらを
エステル交換したものも使用゛することができる。ま友
、この外相油には、必要に応じて、グリセリン脂肪酸モ
ノエステル、ショ糖脂肪酸エステル、プロピレングリコ
ール脂肪酸エステル、ソルビタン脂肪酸部分エステル、
ポリオキシエチレンソルビタン脂肪酸部分エステル、レ
シチン等の乳化剤？併用することができる。Any of vegetable oils and fats such as palm oil, corn oil, coconut oil, coconut oil, and palm kernel oil, animal fats and oils such as milk fat, beef tallow, lard, fish oil, and whale oil can be used. You can also use the replaced one. Mayu, this external phase oil contains glycerin fatty acid monoester, sucrose fatty acid ester, propylene glycol fatty acid ester, sorbitan fatty acid partial ester,
Emulsifier for polyoxyethylene sorbitan fatty acid partial ester, lecithin, etc.? Can be used together.
更に本発明の油脂組成物におけろ水相は特に制限されな
いが、該水相には従来Ｌ９０／Ｗ型エマルジョ／に用い
られている。カゼインを主体とする乳タンパク質を加え
るのが好ましい。この乳タンパク質としては、具体的に
は、ミルクカゼイン。Further, the aqueous phase in the oil and fat composition of the present invention is not particularly limited, but the aqueous phase is conventionally used in L90/W type emulsion/. Preferably, milk proteins, mainly casein, are added. Specifically, this milk protein is milk casein.
カゼインナトリウム、゛カゼインカルシウム、レノネッ
トカゼイ／及び脱脂粉乳等がめげられる。Sodium caseinate, calcium caseinate, lenonet caseinate/and skim milk powder, etc. are recommended.
−本発明の油脂組成物中のリン脂質の量は、 ４？に制
限されるものではないが、油脂組成物全量に対して、目
的とする油脂食品の１日当光りの摂取量から決めるべき
である。通常リン脂質摂取量は成人男子で、全脂質摂取
量の１％〜２０％である。-The amount of phospholipids in the oil and fat composition of the present invention is 4? Although not limited to, it should be determined based on the daily intake of the desired fat and oil food relative to the total amount of the fat and oil composition. Normal phospholipid intake is 1% to 20% of total lipid intake for adult males.
従って本発明エマルジョン中の内相油に含有させる一リ
ン脂質量は１〜２０％、好オしくＦＪ：Ｊ −１０％で
ある。また抗酸化剤の添加量は食品添加物として認めら
れる量１、すなわち最高０．１％でるる。Therefore, the amount of monophospholipid contained in the internal phase oil in the emulsion of the present invention is 1 to 20%, preferably FJ:J -10%. The amount of antioxidant added is 1, which is the amount allowed as a food additive, that is, a maximum of 0.1%.
従って本発明エマルジョン中に添加する量は０．Ｏ１〜
０．１％、好１しくけ０．０５〜０，１％である。ただ
Ｉ、、ｄｌ−α−トコフェロールはこの限りではなく、
任意量添加することができる。Therefore, the amount added to the emulsion of the present invention is 0. O1~
0.1%, preferably 0.05 to 0.1%. However, this is not the case for I,,dl-α-tocopherol,
Any amount can be added.
また、本発明のＯ＋／Ｗ、’Ｏｔ型乳化油脂組成物にお
ける内相油０１、水相Ｗ、外相油０．の１量割合は、内
相油ｏ、 ｔ ｏ〜４０％、水相ｗｔｏ〜４０％、外相
油０，２０〜８０％の範囲が好ましい。Further, in the O+/W and 'Ot type emulsified oil and fat compositions of the present invention, internal phase oil 01, aqueous phase W, and external phase oil 0. The preferred proportions of the internal phase oil are in the range of ~40% for the internal phase oil, ~40% for the water phase wto, and 0.20 ~ 80% for the external phase oil.
本発明のｏ 、／ ｗ１０ｔ型乳化油脂組成物には、更
に必要に応じ、上記のカゼイン會主体とする乳タンパク
質等以外の乳製品、番別、着色料、調味料。The o,/w10t type emulsified oil and fat composition of the present invention may further contain dairy products other than the casein-based milk protein, etc., number, coloring agent, and seasoning, if necessary.
甘味料、糖類２食塩５果汁、及びジャム等を添加するこ
とができ、また、 ０１／Ｗ１０１型乳化油脂組成物の
安定性を高めるために、ゼラチン等の乳化安定用糊料等
の物質を添加しても良い。Sweeteners, saccharides 2 salt 5 fruit juice, jam, etc. can be added, and in order to increase the stability of the 01/W101 type emulsified oil composition, substances such as gelatin and other emulsion stabilizing pastes can be added. You may do so.
本発明の油脂組成物は、リン脂質を安定に保つことがで
きるので、ρｊ脂血症、冒コレステローＡ・血症、動脈
硬化症等の治療、予防のための医薬。Since the oil and fat composition of the present invention can keep phospholipids stable, it can be used as a medicament for the treatment and prevention of ρj lipidemia, cholesterol A bloodemia, arteriosclerosis, and the like.
栄養食品等として有用なものである。It is useful as a nutritional food, etc.
以下に実施例・比較例を挙げ本発明の詳細な説明するが
１本発明はこれらの実施例に限定されるものではない。The present invention will be described in detail below with reference to Examples and Comparative Examples, but the present invention is not limited to these Examples.
実施例１゜
下に示す組成の油脂組成物′に調製した。午の組成物を
４０℃、相対湿度７０％で５力月間保存した後、υノー
ル酸に起因する過酸化物価？測定することにエリ内相油
のシリルオイル型ホスファチジルコリンの安定性ケ調べ
た。この結果全第１表に示す。なお、比較品としてばＷ
、１０及びＯ／Ｗエマルジョンを用いた。Example 1 An oil and fat composition having the composition shown below was prepared. After storing the composition at 40°C and 70% relative humidity for 5 months, the peroxide value due to υnolic acid decreased. To measure the stability of silyl oil type phosphatidylcholine in internal phase oil, we investigated. The results are shown in Table 1. In addition, as a comparison product, W
, 10 and O/W emulsion were used.
（組成）
本発明組成物ｌ：
０、内相油 シリルオイル型ホス ５０ ｇファ
チジルコリ／
し食塩 １０ ｇ
まず、上記の内相油０１成分と水相Ｗ成分全混合し、予
備乳化後、これ會７０℃でホモジナイザーＫかけ、 ０
．／Ｗエマルジョｙを得た。次いで別途用意した上記の
外相油０．成分を６０℃に加熱し、これに上記の０．／
Ｗエマルジョンを加え、混合後、急冷練合せをして、本
発明のｏ、、／Ｗ１０ｔ型乳化油型組化油脂組成物
本発明組成物２：
内相油０．シリルオイル型ホス ５０ ｇファチジル
コリン
ｄｌ−α−トコフェロール ５ｇ外相油０．［大
豆硬化油 ４６０ ｇ実施例りと全て同様にし
て０．、／Ｗ、１０ｙ Ｊ〜’、’ り’ｔ （ｌでＴ
ｊＲ脂組成物金得た。(Composition) Composition 1 of the present invention: 0. Internal phase oil Silyl oil type phos 50 g Fatidyl coli/ Salt 10 g First, the above internal phase oil 01 component and aqueous phase W component were completely mixed, and after preliminary emulsification, this was Homogenizer K at 70℃, 0
．． /W emuljoy was obtained. Next, the above foreign phase oil prepared separately was added. Heat the ingredients to 60°C and add the above 0. /
W emulsion is added, mixed, and then rapidly cooled and kneaded to obtain the O, /W10t type emulsified oil type assembled oil and fat composition of the present invention.Composition 2 of the present invention: Internal phase oil 0. Silyl oil type phos 50 g Fatidylcholine dl-α-tocopherol 5 g External phase oil 0. [Hydrogenated soybean oil 460 g Same as in Example 0.0. , /W, 10y J~','ri't (T with l
jR fat composition was obtained.
比較品１：
油相成分Ｏと水成分Ｗ’に混合し、予備乳化後、これを
７０℃でホモジナイザーを通し、 Ｏ，／Ｗ エマ
ルジョ／を得た。Comparative product 1: Oil phase component O and water component W' were mixed, and after preliminary emulsification, this was passed through a homogenizer at 70°C to obtain O,/W emulsion/.
比較品２：
Ｌ食塩 １０ ｇ比較品ｌと全て
同様にし−ＣＷ１０エマルジョンを得た。Comparative product 2: L common salt 10 g A CW10 emulsion was obtained in the same manner as in Comparative product 1.
（結果）
第１表
以」；の結果から本エマルジョノは、シリルオイル型ホ
スファチジルコリンのリノール酸全安定化させることが
明らかとなり、リン脂質の生理活性を充分に引き出し得
ると判断される。(Results) From the results in Table 1, it is clear that the present emulsion completely stabilizes the linoleic acid of silyl oil type phosphatidylcholine, and is judged to be able to sufficiently bring out the physiological activity of phospholipids.
実施例２゜
実施例１で調製した本発明組成物１〜２及び比較品１〜
２のエマルジョｙｋ、ウィスター系雄性ラット（体重２
００．！ｉ＋）に３ｍｅずつ１５日間胃内投与した。投
与最終日に採血層殺し、血清コレステロール濃度全測定
し７た。また対照として水投与群を設けた。この結果を
第２表に示す。Example 2゜Compositions 1-2 of the present invention prepared in Example 1 and comparative products 1-
2 Emuljo YK, Wistar male rats (weight 2
00. ! i+) was intragastrically administered at 3me doses for 15 days. On the final day of administration, the blood sample was sacrificed and the total serum cholesterol concentration was measured. A water administration group was also provided as a control. The results are shown in Table 2.
第２表
以上の結果から１本発明エマルジョンはリン脂質に’ｆ
定化させ、血清コレステロール低下作用を充分に発揮さ
せうろことが明らかとなった。From the results shown in Table 2, it is clear that the emulsion of the present invention
It has become clear that the serum cholesterol-lowering effect can be fully exerted by stabilizing the serum cholesterol.
以上that's all
Claims (1)
中水中油型乳化油脂組成物。 ２、リン脂質が、ホスフアチジルコリン、ホスフアチジ
ルエタノールアミン、ホスフアチジルイノシトール、ホ
スフアチジルグリセロール、ホスフアチジン酸及びスフ
インゴミエリンから選ばれたリン脂質である特許請求の
範囲第１項記載の油中水中油型乳化油脂組成物。 ３、内相油中に更に抗酸化剤を含有した特許請求の範囲
第１項記載の油中水中油型乳化油脂組成物。[Scope of Claims] 1. An oil-in-water emulsified fat composition characterized by containing a phospholipid in the internal phase oil. 2. The phospholipid according to claim 1, wherein the phospholipid is a phospholipid selected from phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, phosphatidylglycerol, phosphatidic acid, and sphingomyelin. Oil-in-water emulsified fat composition. 3. The oil-in-water emulsified fat composition according to claim 1, which further contains an antioxidant in the internal phase oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61189454A JPS6344842A (en) | 1986-08-12 | 1986-08-12 | O/w/o-type emulsified oil and fat composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP61189454A JPS6344842A (en) | 1986-08-12 | 1986-08-12 | O/w/o-type emulsified oil and fat composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS6344842A true JPS6344842A (en) | 1988-02-25 |
Family
ID=16241523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61189454A Pending JPS6344842A (en) | 1986-08-12 | 1986-08-12 | O/w/o-type emulsified oil and fat composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6344842A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58120815A (en) * | 1982-01-12 | 1983-07-18 | Toyobo Co Ltd | Easily dyeable polyester fiber |
| JP2003213290A (en) * | 2002-01-25 | 2003-07-30 | Snow Brand Milk Prod Co Ltd | Double-emulsified oil and fat composition and method for producing the same |
| EP1618876A1 (en) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for prevention and treatment of atherosclerosis |
| WO2008044550A1 (en) * | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
| US7906488B2 (en) | 2004-11-30 | 2011-03-15 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
| US7968529B2 (en) | 2003-01-20 | 2011-06-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels |
| US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
| US8703172B2 (en) | 2003-01-20 | 2014-04-22 | Nederlandse Organizatie voor Toegepastnatuurwetenschappelijk Onderzoek TNO | Sphingolipids for improvement of the composition of the intestinal flora |
-
1986
- 1986-08-12 JP JP61189454A patent/JPS6344842A/en active Pending
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58120815A (en) * | 1982-01-12 | 1983-07-18 | Toyobo Co Ltd | Easily dyeable polyester fiber |
| JPH0258366B2 (en) * | 1982-01-12 | 1990-12-07 | Toyo Boseki | |
| JP2003213290A (en) * | 2002-01-25 | 2003-07-30 | Snow Brand Milk Prod Co Ltd | Double-emulsified oil and fat composition and method for producing the same |
| US7968529B2 (en) | 2003-01-20 | 2011-06-28 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels |
| US8703172B2 (en) | 2003-01-20 | 2014-04-22 | Nederlandse Organizatie voor Toegepastnatuurwetenschappelijk Onderzoek TNO | Sphingolipids for improvement of the composition of the intestinal flora |
| EP1618876A1 (en) * | 2004-07-19 | 2006-01-25 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Use of sphingolipids for prevention and treatment of atherosclerosis |
| WO2006009436A1 (en) * | 2004-07-19 | 2006-01-26 | Nederlandse Organisatie Voor Toegepast- Natuurwetenschappelijk Onderzoek Tno | Use of sphingolipids for prevention and treatment of atherosclerosis |
| US7906488B2 (en) | 2004-11-30 | 2011-03-15 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
| US8685455B2 (en) | 2005-03-31 | 2014-04-01 | Suntory Holdings Limited | Oil-in-water emulsions containing lignan-class compounds and compositions containing the same |
| WO2008044550A1 (en) * | 2006-10-04 | 2008-04-17 | Suntory Limited | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
| KR101425241B1 (en) * | 2006-10-04 | 2014-08-01 | 산토리 홀딩스 가부시키가이샤 | O/w/o-type emulsion containing lignan compound, and composition comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2006287524B2 (en) | Dietary supplements and prepared foods containing triglyceride-recrystallized non-esterified phytosterols | |
| CA2542504C (en) | Lipids containing omega-3 and omega-6 fatty acids | |
| US3950547A (en) | Dietary composition and methods of preparing | |
| JP3653225B2 (en) | Satisfaction product | |
| TW201438599A (en) | Low viscosity, high caloric density oral nutritional composition and related methods | |
| JP3195594B2 (en) | A food composition containing a milk-derived phospholipid. | |
| WO2005073355A1 (en) | Iron composition | |
| JP2004534793A (en) | Stabilized phytosterol dispersion in oil | |
| JP3891536B2 (en) | Oral composition containing phospholipids derived from mammalian milk | |
| JPS6344842A (en) | O/w/o-type emulsified oil and fat composition | |
| JPS6344843A (en) | O/w/o-type emulsified oil and fat composition | |
| JP2002514394A (en) | Use of nanofoods in human and animal food end products | |
| US2808336A (en) | Oral fat emulsions | |
| JPS6115647A (en) | Oil and fat food | |
| AU2016700A (en) | A pharmaceutical composition comprising cyclosporin in a lipid carrier | |
| US20120282368A1 (en) | Amphiphilic sterol/fat-based particles | |
| JP3247206B2 (en) | Milk composition | |
| JP2003135022A (en) | Coenzyme q10 | |
| JPS6345180B2 (en) | ||
| RU2376781C1 (en) | Revitalising food emulsion "krozam" and its production method | |
| JPS62221629A (en) | Production of phospholipid emulsion | |
| JP2006137730A (en) | Anti-fatigue agent or stamina enhancing agent, functional food or cosmetic | |
| RU2211043C2 (en) | Composition for preparing medicinal forms and enrichment of foodstuffs promoting to correction of disturbances in lipid metabolism, prophylaxis and treatment of atherosclerosis | |
| JPS6098964A (en) | Food for beauty and health | |
| JPS63173555A (en) | Heat-resistant emulsified liquid dressing |